Results of IFN Kinoide on Lupus research are very significant (95% efficacy observed). Volume increase strongly on the biotech and strong breakout of the 0.25 resistance has been observed. Pullback on the 0.25 level is resolved and the stock is now in perfect conditions for a bullish rally. First target is 0.5
Target 10,000. I can't believe I said that... but there is just too much confluence to ignore this possibility. However, a breakdown from this wedge will likely eliminate this play. Either we hit it fast in 2019, or this long is off the table. Let me know your thoughts.
NASDAQ: $QURE looks like it's about to SHIT THE BED! #StayAway ...or consider SHORT'ing if shares are available from your Broker! Looks like an EASY WIN!
Nordic Nanovector $NANO.OL pushing above NOK68 resistance on significant volume, closing at strong 70.3 before weekend. This indicates another attempt at breaking out of long time downtrend that has been effect since ATH back in december 2016. Investors are seemingly very satisified with recent Q3 report and #ASH18 abstracts presented by CEO Eduardo Bravo and his...
Omeros has been consolidating after breaking out of its long downtrend, but looks set to make a new attempt to move upwards, coinciding with a strong move in the $BB etf. Needs volume of trade to confirm this move, while investors are waiting for a list of catalysts to trigger interest.
Prudent Drug Discovery Company Low market cap ( appox £13m at time of writing ). Issues shares very rarely ( last placing nearly four years ago ). Has material interest in its work from larger partners ( Pharmaxis ). Sold interest in LOXL2 programme for £5m to Pharmaxis in December. Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains...
Labu beginning of september had a nice break of prior highs. we have spent the last couple weeks consolidating over that recent high
XBI, LABU, BIB should slide to the bottom of the channel until End-July. See high moving-average divergence, reconvergence and channel pattern. Short unless something changes.
The lower trend line has been very consistent on this stock, and until it breaks, this thing is a winner. Low float, high short interest, potential for huge gains. NASDAQ:APOP
No position yet. Refer to chart:) If you have any thoughts about this company, please leave in the comments:)
1 trend retest 2 trend-based fibo. bounce zone 3 possible three bottoms (Super Pattern)
Tkai massive upside potential. In other words, buy between .99 and current price 1.06 and aim to get out in the 1.2's. Current price is the high point of first wave up (the XA)..price descended appropriately (1--> .618) for support, and moved higher between the 1.21 and 1.41 exetension of XA. The following downtrend in price should suggest a move upwards to at LEAST 1.2s.
It may already be too late to cash in on BSPM
THLD triggered my first level 1.29$ above the pennie mode. Main reason for it might be the release of phase III data from its clinical stage studies of Tarloxotinib. The data will be released somewhere in September. My next levels are 2.15$ and 2.75$.
Elliot wave suggests downward momentum for the past two years, and yesterday NVAX investors got their hearts crushed. Where can it go from here? Based on yesterdays market activity, I see it headed towards the 1.618 retracement regardless of upward or doward movement. so, if it heads further south we could see high 80s but under a dollar, and if demand increases...
Did you ever heard about kidney and heart insufficiencies to be the most accompanying disease? I don't refer on diabetes type 2 but the real first sign an human organism is suffering from serious weakness. Here is DiaMedica with KLK1 and DM199 to reconstruct bradykinin preventing reduced blood flow after strokes or chronical diseases which narrow blood...